News:
| 13-Jan-14 10:00AM | 2:25 am Alnylam Pharma acquires investigational RNAi Therapeutic assets from Merck (MRK) Briefing.com |
| 13-Jan-14 09:54AM | The Deal: Sanofi to Take 12% of Alnylam at TheStreet |
| 13-Jan-14 09:37AM | Sanofi's Genzyme to invest $700M in Alnylam AP |
| 13-Jan-14 09:24AM | Alnylam Wheels, Deals, and Gets $700M Investment From Genzyme at Motley Fool |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-CC5 for the treatment of complement-mediated diseases; ALN-PCS for the treatment of hypercholesterolemia; ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia; and ALN-ANG for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia, and other programs. The company's early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington's disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Address
3rd Floor, 300 Third Street
CAMBRIDGE, MA 02142
United States
CAMBRIDGE, MA 02142
United States
Website
http://www.alnylam.comKey stats and ratios
| Q3 (Sep '13) | 2012 | |
| Net profit margin | -330.17% | -158.88% |
| Operating margin | -358.51% | -194.01% |
| EBITD margin | - | -77.50% |
| Return on average assets | -26.17% | -37.23% |
| Return on average equity | -39.31% | -84.12% |
| Employees | 115 |
No comments:
Post a Comment